Guidelines for chemotherapy of biliary tract and ampullary carcinomas
暂无分享,去创建一个
Masahiro Yoshida | T. Takada | F. Miura | M. Miyazaki | K. Hirata | J. Furuse | M. Nagino | S. Kondo | Hodaka Amano | T. Tsuyuguchi | K. Wada | S. Miyakawa | K. Tsukada | S. Nozawa | H. Saito | F. Kimura | H. Yoshitomi
[1] 日本肝癌研究会. General rules for the clinical and pathological study of primary liver cancer , 2010 .
[2] Masahiro Yoshida,et al. Purpose, use, and preparation of clinical practice guidelines for the management of biliary tract and ampullary carcinomas , 2008, Journal of hepato-biliary-pancreatic surgery.
[3] J. Furuse,et al. S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study , 2008, Cancer Chemotherapy and Pharmacology.
[4] H. Ueno,et al. Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. , 2006, Japanese journal of clinical oncology.
[5] P. Philip,et al. Phase II study of erlotinib in patients with advanced biliary cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] S. Choi,et al. A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer , 2006, Journal of gastroenterology and hepatology.
[7] S. Park,et al. Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma , 2006, Cancer.
[8] 최진섭,et al. Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer , 2006 .
[9] T. Okusaka,et al. Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer , 2006, Cancer Chemotherapy and Pharmacology.
[10] D. Yoon,et al. Capecitabine combined with gemcitabine (CapGem) as first‐line treatment in patients with advanced/metastatic biliary tract carcinoma , 2005, Cancer.
[11] H. Ueno,et al. A phase II trial of Uracil-tegafur (UFT) in patients with advanced biliary tract carcinoma. , 2005, Japanese journal of clinical oncology.
[12] Yeul-Hong Kim,et al. The efficacy of epirubicin, cisplatin, uracil/tegafur, and leucovorin in patients with advanced biliary tract carcinoma , 2005, Cancer.
[13] D. Smith,et al. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer , 2005, British Journal of Cancer.
[14] G. Pond,et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] E. Van Cutsem,et al. A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. , 2005, European journal of cancer.
[16] S. Thongprasert,et al. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] S. Alberts,et al. Gemcitabine, 5‐fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma , 2005, Cancer.
[18] S. Mani,et al. A Phase II Trial of Fixed Dose Rate Gemcitabine in Patients With Advanced Biliary Tree Carcinoma , 2004, American journal of clinical oncology.
[19] H. Ueno,et al. Phase II study of S-1 in patients with advanced biliary tract cancer , 2004, British Journal of Cancer.
[20] C. Tournigand,et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] Manal M. Hassan,et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma , 2004, Cancer.
[22] N. Yonemoto,et al. Chemotherapy in the Treatment of Advanced Gallbladder Cancer , 2004, Oncology.
[23] G. Pond,et al. Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] K. Yeh,et al. Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract , 2004, British Journal of Cancer.
[25] E. Papalambros,et al. Weekly Gemcitabine for the Treatment of Biliary Tract and Gallbladder Cancer , 2004, Investigational New Drugs.
[26] D. Doval,et al. A Phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer , 2004, British Journal of Cancer.
[27] W. Scheithauer,et al. Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] K. Ridwelski,et al. Outpatient Therapy with Gemcitabine and Docetaxel for Gallbladder, Biliary, and Cholangio-Carcinomas , 2002, Investigational New Drugs.
[29] R. Schilsky,et al. Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma , 2004, Investigational New Drugs.
[30] Y. Jan,et al. A phase II trial of tegafur-uracil plus leucovorin (LV) in the treatment of advanced biliary tract carcinomas. , 2003, Japanese journal of clinical oncology.
[31] Helen H. W. Chen,et al. A Phase II Trial of Gemcitabine in the Treatment of Advanced Bile Duct and Periampullary Carcinomas , 2003, Chemotherapy.
[32] H. Ueno,et al. Phase II Study of Cisplatin, Epirubicin, and Continuous-Infusion 5-Fluorouracil for Advanced Biliary Tract Cancer , 2003, Oncology.
[33] Z. Aziz,et al. Prospective Evaluation of Efficacy and Toxicity of 5‐FU and Folinic Acid (Mayo Clinic Regimen) in Patients With Advanced Cancer of the Gallbladder , 2003, American Journal of Clinical Oncology.
[34] J. Kim,et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] R. Goldberg,et al. CPT-11 for bile-duct and gallbladder carcinoma , 2002, International journal of gastrointestinal cancer.
[36] J. Yook,et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[37] T. Takada,et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? , 2002, Cancer.
[38] H. Hass,et al. Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial , 2002, British Journal of Cancer.
[39] M. Ducreux,et al. Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[40] Manal M. Hassan,et al. Phase II Trial of Cisplatin, Interferon α-2b, Doxorubicin, and 5-Fluorouracil for Biliary Tract Cancer , 2001 .
[41] V. Georgoulias,et al. First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II study. , 2001, European journal of cancer.
[42] L. Orlandi,et al. A phase II study of gemcitabine in gallbladder carcinoma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[43] Y. Jan,et al. Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas , 2001, Anti-cancer drugs.
[44] W. Scheithauer,et al. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[45] J. Seo,et al. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. , 2000, American Journal of Clinical Oncology.
[46] T. Todoroki. Chemotherapy for gallbladder carcinoma--a surgeon's perspective. , 2000, Hepato-gastroenterology.
[47] M. Ducreux,et al. A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. , 2000, European journal of cancer.
[48] W. Scheithauer,et al. Two Consecutive Phase II Studies of 5-Fluorouracil/Leucovorin/Mitomycin C and of Gemcitabine in Patients with Advanced Biliary Cancer , 1999, Oncology.
[49] R. Pazdur,et al. Phase II trial of docetaxel for cholangiocarcinoma. , 1999, American journal of clinical oncology.
[50] T. Takada,et al. Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial. , 1998, Hepato-gastroenterology.
[51] R. Jenkins,et al. A phase II trial of 5‐fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma , 1998, Cancer.
[52] Y. Jan,et al. Weekly 24 h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract carcinomas. , 1998, Anti-cancer drugs.
[53] M. Ducreux,et al. Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[54] G. Colucci,et al. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5‐fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule: Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.) , 1996, Cancer.
[55] T. Linné,et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[56] A. Hoque,et al. Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] C. Charnsangavej,et al. Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] T. Hickish,et al. Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. , 1995, European journal of cancer.
[59] T. Takada,et al. Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. , 1994, Oncology.
[60] J. Furuse,et al. A phase II study of cisplatin in patients with biliary tract carcinoma. , 1994, Oncology.
[61] S. Pyrhönen,et al. Epirubicin‐Sequential Methotrexate‐5‐Fluorouracil‐Leucovorin Treatment in Advanced Cancer of the Extrahepatic Biliary System: A Phase II Study , 1994, American journal of clinical oncology.
[62] R. Audisio,et al. Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group Study. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.
[63] P. Schein,et al. 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] C. Moertel,et al. Eastern cooperative oncology group experience with chemotherapy for inoperable gallbladder and bile duct cancer , 1984, Cancer.
[65] I sabel Mortara,et al. International Union against Cancer , 1938, Nature.